ABSTRACT
The present study aims to investigate the hepatoprotective effect of Eucalyptus globulus extract against pesticide liver damage in comparison to silymarin, a classical antioxidant liver medicine. Liver damage was induced by oral administration of toxicant i.e. Glufosinate ammonium. The extent of damage was studied by assessing biochemical parameters and histopathological evaluations. The aqueous extracts of Eucalyptus globulus were administered respectively to the animals pretreated with pesticide and its effects on biochemical parameters were compared with standard drug silymarin (100mg/kg b.wt). Eucalyptus globules showed significant reduction of serum enzymes AST, ALT, ALP & Bilirubin (Aspartate Transminase, Alanine Transminase, Alkaline Phosphatase & Total bilirubin) when compared to control counterparts. The hepatoprotective effect of Eucalyptus globules was comparable with the standard drug silymarin and it was confirmed by histopathological findings. Moreover, these effects presented in a dose-dependent manner.The present study showed that aqueous extract of Eucalyptus globulus at the dosage level of 500 mg/kgb.wt may play a protective role against pesticideinduced hepatotoxicity
ABSTRACT
BACKGROUND: The dose requirements for oral anticoagulants in thromboembolic events are influenced by promoter polymorphism in the VKORC1 gene. However, limited data are available on the influence of the polymorphism in various Indian populations. The present study aimed at determining the relationship between the VKORC1-1639 G>A genotypes and maintenance doses of oral anticoagulants for therapeutically stable INR values in patients taking Acitrom after valve replacement surgery. MATERIALS AND METHODS: Fifty patients from the northern Indian region were genotyped for VKORC1-1639 G>A by polymerase chain reaction and restriction fragment length polymorphism. Means of the weight-normalized daily Acitrom dose were calculated for every patient. RESULTS AND DISCUSSION: The VKORC1 1639G>A minor allele frequency in the study population (n = 50) was found to be 22%. The patients with a wild type genotype required the maximum drug dose as suggested for full functionality of the enzyme. Heterozygous patients were found to have an intermediate drug dose and the patients with a variant homozygous genotype had the minimum maintenance drug dose requirement. These findings are in concurrence with the effect of the promoter polymorphism on vitamin K epoxide reductase activity.1639G>A minor allele frequency in the study population (n = 50) was found to be 22%. The patients with a wild type genotype required the maximum drug dose as suggested for full functionality of the enzyme. Heterozygous patients were found to have an intermediate drug dose and the patients with a variant homozygous genotype had the minimum maintenance drug dose requirement. These findings are in concurrence with the effect of the promoter polymorphism on vitamin K epoxide reductase activity. CONCLUSION: The VKORC1-1639 G>A status can be indicative of establishing the therapeutic dose of oral anticoagulants in Indian patients.